摘要
目的:研究在“胃-清浊生华-骨生成”理论指导下蒙药那仁满都拉治疗原发性骨质疏松症,是否改善骨密度、骨强度、骨痛等临床症状,论证该药物的临床疗效,为科学治疗提供参考。方法:选取2020年1月—2021年12月,于内蒙古医科大学第一附属蒙医中医医院骨伤科就诊的90例原发性骨质疏松症患者,予那仁满都拉口服,于治疗前、治疗后,比较骨密度、疼痛评分、蒙医证候积分,观察临床疗效。结果:那仁满都拉治疗原发性骨质疏松症总有效率为94.44%(85/90)。治疗前骨密度、VAS评分及蒙医证候积分与治疗后比较,差异具有统计学意义(P<0.05)。结论:那仁满都拉口服可有效提高原发性骨质疏松症患者骨密度,减轻疼痛,临床疗效良好。
Objective:Under the guidance of the theory of"stomach-Clear turbid and blooming-bone ogenesis",this study aims to investigate whether the Mongolian medicine Narenmandula can improve clinical symptoms such as bone density,bone strength,and bone pain in the treatment of primary osteoporosis,and to demonstrate its clinical efficacy,providing reference for scientific research.Methods:From January 2020 to December 2021,90 patients with primary osteoporosis who were treated in the Department of Orthopedics and Traumatology of the Mongolian Medical Hospital Affiliated to Inner Mongolia Medical University were selected and given Narenmandula orally.The patients'bone mineral density,pain score,and Mongolian medical syndrome score were collected before and after treatment to observe their clinical efficacy.Results:The total effective rate of Narenmandula was 94.44%(85/90).Before treatment,the bone mineral density,VAS score and TCM syndrome score of patients were compared with those after treatment,and the differences were statistically significant(P<0.05).Conclusion:Narenmandula oral administration can effectively improve bone density,alleviate pain,and have a good clinical effect in patients with primary osteoporosis.
作者
郭贡布扎布
肖吉日木图
Guogongbuzhabu;Xiaojirimutu(Inner Mongolia Bayannur Urad Houqi Mongolian Medical Hospital,Bayannur 015599,China;Inner Mongolia Medical University,Hohhot 010110,China)
出处
《中国民族医药杂志》
2023年第8期24-26,共3页
Journal of Medicine and Pharmacy of Chinese Minorities
关键词
骨质疏松症
那仁满都拉
临床观察
Primary Osteoporosis
Narenmandula
Clinical research
